| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.3 | 10.0 |
| Net income | -21.6 | -24.3 |
| EPS (diluted, $ a share) | $-0.34 | $-0.39 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -7.1% |
|---|---|
| Operating margin | -336.5% |
10-Q filed with the SEC, NASDAQ: JANX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Janux Therapeutics, Inc.: key numbers
- Share price
- $10.71Close, Nov 17
- Market cap
- $655M
- Shares outstanding
- 61.18MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Janux Therapeutics, Inc.
All →Janux Therapeutics Financial Results
Janux Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a strong cash position of $945.7 million. The company continues to advance its clinical pipeline, including dosing the first patient in a Phase 1 study of JANX013 and preparing for an upcoming data presentation for JANX011.
“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007. We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.”
David Campbell, Ph.D., President and Chief Executive Officer